Neurocrine Biosciences shares drop as trial failures may ‘stunt momentum,’ analysts say
November 10, 2023 at 08:59 AM EST
Company will halt development of experimental depression treatment
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
| ||||||